| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/17/2013 | CA2690773C Pharmaceutical liquid composition of botulinum toxin with improved stability |
| 09/17/2013 | CA2685349C Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
| 09/17/2013 | CA2673646C Formation of medically useful gels comprising microporous particles and methods of use |
| 09/17/2013 | CA2568171C Oral administration form comprising probiotic bacteria |
| 09/17/2013 | CA2550983C Enhanced absorption of modified release dosage forms |
| 09/17/2013 | CA2549916C Transdermal delivery system of hormones without penetration enhancers |
| 09/17/2013 | CA2546794C Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients |
| 09/17/2013 | CA2470377C Solid dosage form for the ocular administration of an active principle, a soluble, solid ophthalmic insert and the production method thereof |
| 09/17/2013 | CA2445381C Phosphorous antimicrobial compounds and methods for their use |
| 09/12/2013 | WO2013134636A1 Compositions and methods for delivery of kinase inhibiting peptides |
| 09/12/2013 | WO2013134362A1 Improved stability of hydromorphone hydrochloride solutions |
| 09/12/2013 | WO2013134349A1 Delivery systems for enhancing drug efficacy |
| 09/12/2013 | WO2013134348A1 Controlled-release solid dosage forms of mesalamine |
| 09/12/2013 | WO2013134279A1 Wireless communication for on-body medical devices |
| 09/12/2013 | WO2013134089A1 Nanoparticles coated with amphiphilic block copolymers |
| 09/12/2013 | WO2013133927A1 Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
| 09/12/2013 | WO2013133783A1 Composition and methods to enhance anti-oxidation, gut flora and immunity in pets |
| 09/12/2013 | WO2013133702A1 Methods and compositions for stabilizing dried biological materials |
| 09/12/2013 | WO2013133620A1 Pharmaceutical composition comprising clopidogrel and aspirin and process for preparing the same |
| 09/12/2013 | WO2013133543A1 Calcium carrier, and chelated calcium pha granule and microorganism comprising same |
| 09/12/2013 | WO2013133448A1 Sustained release oral solid preparation |
| 09/12/2013 | WO2013133413A1 Mucosa-elevating agent |
| 09/12/2013 | WO2013133408A1 Liquid medicine for internal use |
| 09/12/2013 | WO2013133405A1 Pharmaceutical composition containing peptide |
| 09/12/2013 | WO2013133388A1 Adhesive patch |
| 09/12/2013 | WO2013133387A1 Adhesive patch |
| 09/12/2013 | WO2013133062A1 Coating agent for allergic rhinitis |
| 09/12/2013 | WO2013132670A1 Semi-solidified nutritive agent |
| 09/12/2013 | WO2013132457A2 Nanocrystalline solid dispersion compositions and process of preparation thereof |
| 09/12/2013 | WO2013132083A1 Dispersion containing dispersed bodies, each comprising an internal drop and a membrane |
| 09/12/2013 | WO2013132058A1 Diagnostic chewing gum for pathogens |
| 09/12/2013 | WO2013131988A1 Composition for care and hygiene of the ear canal |
| 09/12/2013 | WO2013131987A1 Anti-p-selectin antibody formulation |
| 09/12/2013 | WO2013131986A1 Production of pharmaceutical protective coatings with good resistance in a neutral environment |
| 09/12/2013 | WO2013131967A1 Pharmaceutical compositions comprising metformin and a dpp -4 inhibitor or a sglt-2 inhibitor |
| 09/12/2013 | WO2013131866A1 Abeta antibody formulation |
| 09/12/2013 | WO2013131164A1 Pharmaceutical composition containing conventional liposomes and prolonged-circulation liposomes for the treatment of visceral leishmaniasis |
| 09/12/2013 | WO2013131157A1 Combination of a monosubstituted sulfamate derivative of the natural monosaccharide d-fructose (topiramate) with an anti-depressant from the phenyl ketone class (bupropion) for treating obesity and plurimetabolic syndromes |
| 09/12/2013 | WO2013106944A3 Method for selective targeting of nanoencapsulated cells on target tissue or organs |
| 09/12/2013 | WO2013105026A4 A process for preparing solid lipid sustained release nanoparticles for delivery of vitamins |
| 09/12/2013 | WO2013092673A3 New combination |
| 09/12/2013 | WO2012100366A8 Liposome and personal care composition comprising thereof |
| 09/12/2013 | US20130237611 Aqueous formulations of (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate |
| 09/12/2013 | US20130237608 Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol |
| 09/12/2013 | US20130237603 Acetylcysteine Compositions and Methods of use Thereof |
| 09/12/2013 | US20130237602 Valproic acid drug delivery systems and intraocular therapeutic uses thereof |
| 09/12/2013 | US20130237576 Dexmedetomidine Premix Formulation |
| 09/12/2013 | US20130237574 Tablet formulations comprising valsartan |
| 09/12/2013 | US20130237570 Formulation and Use and Manufacture Thereof |
| 09/12/2013 | US20130236557 Oil-in-Oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| 09/12/2013 | US20130236556 Compositions and methods relating to reduced mucoadhesion |
| 09/12/2013 | US20130236554 Dosage forms for oral administration and methods of treatment using the same |
| 09/12/2013 | US20130236553 Compositions and Methods for the Delivery of Therapeutics |
| 09/12/2013 | US20130236552 Nanotopography-mediated reverse uptake platform for nucleic acid delivery and applications thereof |
| 09/12/2013 | US20130236551 Combination composition useful for treating cardiovascular diseases |
| 09/12/2013 | US20130236550 Pharmaceutical microparticles |
| 09/12/2013 | US20130236548 Method for treating cancer by using Fe-based particles |
| 09/12/2013 | US20130236545 Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria |
| 09/12/2013 | US20130236543 Pharmaceutical composition and uses thereof |
| 09/12/2013 | US20130236542 Slow release magnesium composition and uses thereof |
| 09/12/2013 | US20130236540 Oral dosage form of 25-hydroxyvitamin d |
| 09/12/2013 | US20130236539 Method of reducing somnolence in patients treated with tizanidine |
| 09/12/2013 | US20130236538 Pharmaceutical compositions of ibuprofen and famotidine |
| 09/12/2013 | US20130236537 Pharmaceutical preparation for tumor chemotherapy and method for producing the same |
| 09/12/2013 | US20130236534 Modified drugs for use in liposomal nanoparticles |
| 09/12/2013 | US20130236530 Pain reliever composition |
| 09/12/2013 | US20130236529 Composition and methods to enhance anti-oxidation, gut flora and immunity in pets |
| 09/12/2013 | US20130236527 Licorice lollipop that inhibits dental caries formation |
| 09/12/2013 | US20130236526 Sustained Release Intraocular Implants and Methods for Preventing Retinal Dysfunction |
| 09/12/2013 | US20130236525 Sustained release intraocular implants and related methods |
| 09/12/2013 | US20130236524 Silicone coated implant |
| 09/12/2013 | US20130236518 Materials and methods for delivering compositions to selected tissues |
| 09/12/2013 | US20130236516 Felbinac-Containing External Patch |
| 09/12/2013 | US20130236515 Levalbuterol salt |
| 09/12/2013 | US20130236514 Pharmaceutical Compositions Comprising Terbinafine |
| 09/12/2013 | US20130236511 Formulation and manufacture of pharmaceuticals by impregnation onto porous carriers |
| 09/12/2013 | US20130236509 Microparticles comprising a small heat-shock protein |
| 09/12/2013 | US20130236507 Method for treating cancer by using Fe-containing alloy particles |
| 09/12/2013 | US20130236505 Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment |
| 09/12/2013 | US20130236501 Injectable Emulsion of Sedative Hypnotic Agent |
| 09/12/2013 | US20130236500 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same |
| 09/12/2013 | US20130236499 Segmented, Semicrystalline Poly(Lactide-co-epsilon-Caprolactone) Absorbable Copolymers |
| 09/12/2013 | US20130236498 Biodegradable supporting device |
| 09/12/2013 | US20130233748 Abuse Potential Reduction in Abusable Substance Dosage Form |
| 09/11/2013 | EP2636739A1 iRNA agents targeting VEGF |
| 09/11/2013 | EP2636408A1 Patch |
| 09/11/2013 | EP2636405A1 Felbinac-containing external patch |
| 09/11/2013 | EP2636404A2 Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products |
| 09/11/2013 | EP2636403A1 Production of pharmaceutical protective overalls with good resistance in a neutral environment |
| 09/11/2013 | EP2635522A2 Nanoimprint lithography formation of functional nanoparticles using dual release layers |
| 09/11/2013 | EP2635293A1 Skin wound healing compositions and methods of use thereof |
| 09/11/2013 | EP2635291A1 Plant extracts for treating burns and chronic wounds |
| 09/11/2013 | EP2635287A1 Administration of nedd8-activating enzyme inhibitor |
| 09/11/2013 | EP2635283A2 Methods for treatment of brain injury utilizing biologics |
| 09/11/2013 | EP2635282A1 Compositions and methods for treating myelofibrosis |
| 09/11/2013 | EP2635273A2 Isoflavonoid compositions and methods for the treatment of cancer |
| 09/11/2013 | EP2635272A1 Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms |
| 09/11/2013 | EP2635269A1 A combination composition |
| 09/11/2013 | EP2635265A2 Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery |
| 09/11/2013 | EP2635264A1 Formulations comprising polyethylene glycol |